For people living with Type 1 Diabetes (T1D), keeping blood sugar levels in check is a constant challenge. A new clinical trial at UVA is aiming to simplify diabetes management by testing an ...

Beta Bionics’ IPO marks one of the largest public offerings for an Orange County-based company in over three years, second ...

Completing the CE Mark submission for Eversense 365 brings us a step closer to improving lives and health outcomes for ...

Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Patients who use smartphone apps to manage their diabetes could face serious health problems if they miss notifications ...